title: What constitutes scientific justification for inclusion of recovery assessment in pre-clinical studies supporting first time in man (FTIM)?
authors.affiliation: Drug Safety and Metabolism, AstraZeneca, Alderley Park, Macclesfield, UK.
authors.forename: Sally
authors.initials: S
authors.lastname: Robinson
authors.affiliation: Drug Safety and Metabolism, AstraZeneca, Alderley Park, Macclesfield, UK. Electronic address: ruth.roberts@astrazeneca.com.
authors.forename: Ruth
authors.initials: R
authors.lastname: Roberts
mesh_terms: D035843:Biomedical Research / Q000379:methods; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical / Q000379:methods; D064420:Drug-Related Side Effects and Adverse Reactions; D015507:Drugs, Investigational / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans
chemical_list: D015507:Drugs, Investigational